Therapeutic Adherence

2

Review clinical trials related to Therapeutic Adherence. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Improving Patients' Adherence to Their Chronic Treatments by Implementing a Simple, Standardized and Redundant Message Delivered by Healthcare Professionals.

The primary objective in this study is to achieve a 15% 6-month improvement in therapeutic adherence among patients with chronic pathologies, thanks to a simple, standardized and redundant message delivered by healthcare professionals during consultations/interviews Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action concerning therapeutic adherence. This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake.

Participants needed: 1,210
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Jul 1, 2026Locations: 10
Eligibility criteria

Adult patients (age ≥ 18 years) [+3]

Patients included in the control period. [+3]

Status: Recruiting

Cholesterol Self-testing in Patients Post Acute Coronary Syndrome

The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events. The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of LeipzigUpdated: Aug 1, 2024Locations: 1
Eligibility criteria

Age ≥ 18 years [+2]

Persons unable to understand the study [+5]